**EDITORIAL**

Management of hemangioblastomas in patients with von Hippel–Lindau disease: stereotactic radiosurgery compared to surgical excision

Edward H. Oldfield, MD

Department of Neurological Surgery, University of Virginia Health Science Center, University of Virginia, Charlottesville, Virginia

Kano and colleagues report the results of the analysis of a retrospective, multinational, multinational experience with stereotactic radiosurgery (SRS) for hemangioblastomas (HBs) of the brain from 19 centers. Their report includes treatment of 335 HBs in 80 patients with von Hippel–Lindau disease (VHL) and 182 sporadic HBs in 106 patients.

My comments are mainly related to the patients with VHL, as all of the information on the natural history of HBs, essential information for selection of the most appropriate therapy and when to use it, is from studies of patients with VHL, since these patients are the patients with HBs who are followed with serial brain and spinal MRI.

**Lesions Selected for Treatment Differ Greatly Between SRS and Surgery**

It is clear from this study as well as other studies of SRS for HBs that in VHL the reports on the experience with SRS describe an entirely different set of patients compared to the surgical series; the SRS experience is almost entirely comprised of tumors that are either small HBs or a residual of unsuccessful surgery, HBs that are visible on MRI but that would not be candidates for surgical treatment. The HBs treated by SRS are smaller, generally so small that they are not producing symptoms, and are less likely to have an associated cyst than are the HBs treated with surgery. For instance, in the Kano series of SRS the mean tumor size was 0.9 cm³ for the 335 treated tumors in the VHL patients. This compares to an average size of 2.4 cm³ in the NIH surgical series of all 164 cerebellar HBs in VHL, 4.0 cm³ in the 46 HBs (28%) not associated with cysts, but 16.5 cm³ total volume in the 118 HBs (72%) associated with cysts (so large that it is far off the scale of the graph). (See Fig. 1A.)

Kano et al. describe 48 of their 80 VHL patients treated with SRS as having symptoms. Almost all patients with VHL with symptoms from an HB of the brain have the symptoms from one, rather than the combined effects of more than one tumor. Thus, we can assume that only 48 of the 335 SRS-treated HBs were producing symptoms (14%). This compares to symptoms in 96% of the patients receiving surgery at the NIH (Fig. 1B), a series in which 83% of the resected HBs produced symptoms and 17% were resected as a result of being in the surgical field during surgery for a patient with a symptom-producing HB.

Cysts associated with the HB are often the largest component of the space-occupying lesion, and the great majority of symptom-producing HBs are associated with a cyst that is larger than the tumor causing it. In even greater emphasis on the great difference in the tumor size in SRS-treated versus surgical patients with HBs, only 11% of the 335 tumors in VHL patients had associated cysts in the report by Kano et al.; this compares to 72% with cysts in the 164 resected HBs in the NIH series. Moreover, if the mass contributed by the cyst is included, the mean total volume of the lesions with cysts in the NIH series was 16.5 ± 14 cm³. The difference in the percentage of treated lesions that were producing symptoms in these two series, one a large SRS series, the other a large surgical series in which patients were selected for treatment only when they had symptoms, is clearly a reflection of differences in patient selection based on symptom production dictating who was, or was not, a candidate for treatment.

Thus, in general, there are clearly substantive differences in the circumstances in which SRS and surgery have been used in patients with VHL; most of the lesions selected for surgical treatment were much larger, more likely to have associated cysts increasing the mass effect further, and were producing symptoms, whereas almost all the HBs treated with SRS have been small HBs that were detected on MRI, but were too small to produce symptoms. Despite these great differences, most of the reports of SRS for these tumors attempt to compare the
risks of SRS versus surgical treatment, comparisons that are clearly invalid.

**Risks Associated With Treatment**

Kano et al. report complications associated with SRS in 13 of the total of 186 patients treated (7%: they do not distinguish complications between the VHL and sporadic HB patients). Eleven of the 13 patients required steroid therapy for treatment-induced edema surrounding the tumor, 1 patient died of refractory peritumoral edema, and 2 patients required surgery (one for hydrocephalous, one for peritumoral cyst drainage). In addition, 19% of the VHL patients required additional treatment for progression of a treated tumor.

In the surgical series from the NIH, immediately after tumor resection, patients were stable or improved after 88% of operations; in 12% of operations there were new cerebellar signs and symptoms or exacerbation of pre-existing symptoms. However, these new symptoms and signs were frequently mild in nature and resolved rapidly (mean resolution time 9.3 ± 2.2 days) in all but 1 case. By 3 months after surgery, patients were at their preoperative status or improved after 98% of the operations. All patients without preoperative signs or symptoms remained asymptomatic after resection. No patient died as a result of surgical treatment. Since there was complete excision of all tumors, no treated tumor required additional treatment.

**Optimal Management of HBs in VHL**

Is SRS the best management for small HBs in VHL that are not producing symptoms? How does the natural history of the HBs treated with SRS compare to the natural history of untreated HBs in VHL?

To establish whether SRS is a reasonable option for small HBs that are not producing symptoms in patients with VHL requires analysis of the natural history of SRS-treated HBs that were not causing symptoms compared to the natural history of similar lesions that were not treated. Unfortunately, there are no randomized studies addressing this important issue. However, we can benefit from assessing the information that is available. Lonser et al. recently reported the results of a large prospective study of the natural history of 2505 untreated HBs, 1302 (52%) of which were in the cerebellum or brainstem, in 225 patients with VHL. Their study included clinical and imaging assessment every 6 months for a mean of 6.9 years. Further, note that that study included untreated HBs with cysts, peritumoral edema, and new lesions. Two hundred ninety-two new cerebellar HBs arose during the 6.9 years of the study, and 50% of the HBs in the cerebellum progressed at 6.2 years. In most lesions the growth was a stuttering, on-off, type of growth (this occurred in 72% of the lesions that enlarged), and the great majority of HBs that demonstrated growth produced no symptoms and did not require treatment. At last evaluation only 159 (6.3%) of the 2505 HBs produced symptoms and required treatment over the mean evaluation of 6.9 years.

Of the 335 HBs in VHL patients treated with SRS in the current study, only 14% of which were symptom-producing, and over the mean follow-up of 5.5 years, 26 (8%) HBs progressed despite the treatment. As the authors indicate, the lesions selected for treatment either were lesions that had shown growth on serial MRI, were new lesions on MRI, or were producing symptoms. Thus, there was selection for tumors that may have had a greater likelihood of progression over time than would have been the case if all MRI-visible lesions were assessed. However, despite the